Figures
- FIGURE 1
CONSORT diagram. VAS: visual analogue scale; LCQ: Leicester cough questionnaire; KSQ: King's sarcoidosis questionnaire.
- FIGURE 2
Number of coughs in 24 h. Individual subject data showing 24-h cough counts at baseline and during treatment with azithromycin for 1 month and 3 months.
- FIGURE 3
Patient-reported outcomes. Individual subject data showing: a) cough severity visual analogue scale (VAS); b) urge to cough VAS; c) Leicester cough questionnaire (LCQ) scores; and d) King's sarcoidosis questionnaire (KSQ) general health scores at baseline and during treatment with azithromycin for 1 month and 3 months. VAS are 100 mm scales with lower numbers indicating lower cough severity and urge to cough. Higher scores on LCQ and KSQ indicate better cough- and sarcoidosis-related quality of life respectively.
Tables
- TABLE 1
Demographic and clinical details of 21 recruited patients with sarcoidosis
Age years 57 (48–71) Male/female 9/12 Years since diagnosis 3 (1–13) Scadding chest radiography stage 1/2/3 2/6/13 FEV1 % predicted 87.5 (52–131) FVC % predicted 91.5 (63–128) FEV1/FVC ratio 0.75 (0.55–0.93) QTc interval ms 427 (370–463) Oral corticosteroid therapy 5 Other immunomodulatory therapy 0 Inhaled corticosteroids 3 Number of coughs in 24 h 228 (43–1950) Number of coughs·h−1 10 (2–81) Cough severity VAS mm 31 (9–94) Urge to cough VAS mm 26 (8–94) Leicester cough questionnaire score 15.96 (5.07–19.74) King's sarcoidosis questionnaire GH score 50.7 (23.8–100) Data are presented as median (range) or n. FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; VAS: visual analogue scale.
- TABLE 2
Secondary end-points
Baseline 1 months 3 months Change from baseline at 3 months p-value (Friedman's test) Cough severity VAS Median 30.5 (9, 94)
Mean 38.8 (25.7)24.0 (3, 88)
33.7 (25.2)19.0 (0, 62)
19.8 (17.7)−9.0 (−93, 20)
−18.1 (27.6)0.009 Cough urge VAS Median 26.0 (8, 94)
Mean 38.7 (26.2)26.0 (2, 83)
32.5 (23.3)18.5 (0, 61)
22.2 (18.3)−13.0 (−83, 42)
−15.7 (27.9)0.066 LCQ Median 15.96 (5.07, 19.74)
Mean 14.63 (4.07)17.6 (6.11, 20.75)
16.68 (3.41)19.02 (14.93, 20.38)
18.23 (1.76)1.85 (−1.17, 12.18)
3.47 (4.0)0.006 KSQ_GH Median 50.7 (23.8, 100)
Mean 52.93 (18.3)61.9 (29.4, 100)
63.0 (18.1)72.25 (39.9, 100)
69.63 (15.4)16.3 (−13.8, 47.1)
17.5 (15.8)0.001 KSQ_lung Median 50.2 (29.0, 68.0)
Mean 52.0 (10.4)52.6 (33.6, 77.1)
54.5 (12.0)61.95 (41.6, 100)
62.5 (14.0)6.5 (−1.3, 34.8)
10.7 (11.3)0.001 KSQ_lung_GH Median 58.1 (36.7, 74.7)
Mean 57.3 (9.1)58.7 (41.9, 86.1)
61.9 (11.6)66.25 (50.1, 91.5)
67.58 (10.4)10.7 (−2.3, 26.8)
10.6 (8.3)0.0001 Data are presented as median (range) and mean (sd). VAS: visual analogue scale; LCQ: Leicester cough questionnaire; KSQ: King's sarcoidosis questionnaire (presented as general health (GH), lung and combined lung-GH domains).
